(VCBeat) Mar. 5, 2021 -- Boston Scientific (NYSE: BSX), one of the world's leading medical technology companies, has entered into a strategic partnership with Chengdu New Radiomedicine Technology Co., Ltd. ("CNRT") for equity investment, technology transfer, and local production. This is the first time that Boston Scientific has cooperated with a local Chinese enterprise concerning technology transfer and localized production, which marks an important milestone for Boston Scientific to accelerate the localization process and deepen its strategic layout in western China.

In this collaboration, Boston Scientific will transfer the TheraSphereTM Y90 glass microsphere technology to CNRT, in order to accelerate the introduction of this global leading medical product for the benefit of patients with liver cancer in China. In addition, Boston Scientific will support the development of CNRT's innovative products and get the rights to market them both domestically and internationally. In addition, Boston Scientific has made a strategic investment in NRT, becoming one of the major shareholders of the company.

Zhang Jun, president of Boston Scientific China, said: "In the future, we hope to deepen cooperation with more local partners, accelerate the integration of China with international medical innovation, make the high-quality medical resources more accessible and more timely, help to realize the vision of "Healthy China" with a never-changing commitment to 'Advancing science for life'."

Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. It is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

CNRT is a Chinese  medical isotopes provider. The company's business covers research, manufacture and sales for medical isotopes and products. We provide services for malignant tumor diagnosis and treatments and radionuclides medicine technology support and consulting.